Tuberculosis after a borderline QuantiFERON result during screening before infliximab by Uzorka, J.W. et al.
  
 
 
 
 
Tuberculosis after a borderline QuantiFERON result during 
screening before infliximab 
 
 
Journal: European Respiratory Journal 
Manuscript ID ERJ-00913-2018.R1 
Manuscript Type: Correspondence 
Date Submitted by the Author: n/a 
Complete List of Authors: Uzorka, Jonathan; Infectious diseases 
Delfos, Nathalie 
Witte, Anne 
Scheper, Henk 
van Soolingen, Dick; Rijksinstituut voor Volksgezondheid en Milieu, IDS 
Arend, Sandra M.; LUMC, Infectious Disease 
Key Words: 
Monoclonal Antibodies, Infliximab, Latent Tuberculosis, Tuberculosis, 
Interferon-gamma Release Tests 
  
 
 
European Respiratory Journal
Dep t .  Infectious Diseases t o  The Editors of  
 
p o s t zon e  C-05-P  European Respiratory Journal 
 J.W. Uzorka   
    
p h on e  +31 71 5262620  f a x  +31 71 5266758   
e -ma i l  j.w.uzorka@lumc.nl    
o u r  r e f e r en c e  ERJ-00913-2018   
yo u r  r e f e r e n c e     
d a t e  June 5th 2018   
s u b j e c t  Resubmission original manuscript   
   
Dear Prof. G.B. Migliori, Prof. M. Kolb and Prof. J. Chalmers, 
 
Thank you very much for your email of May 30 with  the invitation to revise manuscript ERJ-
00913-2018. We also thank the reviewers for the critical and useful comments and suggestions, 
which we have used for the revision as indicated point by point.  
 
We hereby submit the revised versions of the manuscript entitled ‘Tuberculosis after a borderline 
QuantiFERON result during screening before infliximab’, one in which all changes are in red and 
one without.  
 
With kind regards, 
 
Jonathan W. Uzorka 
 
Corresponding author:  
Jonathan W. Uzorka, M.D. 
Department of Infectious Diseases, C05-P 
Leiden University Medical Center 
Albinusdreef 2 
2333 ZA Leiden 
The Netherlands 
Phone: +31 71 5264915 
Fax: +31 71 5266758 
Email: j.w.uzorka@lumc.nl 
 
Page 1 of 18 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tuberculosis after a borderline QuantiFERON result during screening before 1 
infliximab 2 
 3 
Jonathan W. Uzorka M.D.
1*
, Nathalie M. Delfos M.D.
2
, Anne M.C. Witte M.D, Ph.D.
3
, Henk 4 
Scheper M.D.
 1
, Dick van Soolingen Ph.D.
4
, Sandra M. Arend M.D., Ph.D.
1
 5 
 6 
Author’s affiliations: 7 
1. Department of Infectious Diseases, Leiden University Medical Center, C5-P40, 8 
Albinusdreef 2, 2333 ZA Leiden, The Netherlands 9 
2. Department of Internal Medicine, Alrijne Ziekenhuis, Simon Smitweg 1, 2353 GA 10 
Leiderdorp, The Netherlands 11 
3. Department of Gastroenterology and Hepatology, Alrijne Ziekenhuis, Simon Smitweg 12 
1, 2353 GA Leiderdorp, The Netherlands 13 
4. Tuberculosis Reference Laboratory, National Institute for Public Health and the 14 
Environment, Bilthoven, The Netherlands 15 
 16 
Word count: 928 17 
Keywords: Monoclonal Antibodies; Infliximab; Latent Tuberculosis; Tuberculosis; 18 
Interferon-gamma Release Tests;  19 
  20 
*Corresponding author: 21 
Jonathan W. Uzorka M.D. 22 
Department of Infectious Diseases, C5-P 23 
Leiden University Medical Center 24 
Albinusdreef 2 2333 ZA Leiden, The Netherlands 25 
Phone: +31 71 5262620 26 
Fax:+31 71 5266758 27 
Email: j.w.uzorka@lumc.nl 28 
 29 
Summary: Development of tuberculosis after a borderline QuantiFERON result during 30 
screening before TNF-α antagonist therapy  31 
  32 
Page 2 of 18European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
To the Editor: 33 
Patients who are eligible for treatment with immunosuppressive drugs such as antagonists of 34 
tumour necrosis factor-α (TNF-α) must be screened for latent tuberculosis infection (LTBI), 35 
as stated in the recent European Standards for TB Care [1]. Although there are controversies 36 
regarding optimal screening [2], interferon gamma release assays (IGRA) such as 37 
QuantiFERON-TB Gold (QFT) are nowadays frequently used. The formal cut-off for a 38 
positive QFT is ≥ 0.35 IU/mL interferon-γ. However, a recent study published in European 39 
Respiratory Journal found that a significant proportion of results just below this cut-off, so 40 
called ‘borderline results’, represented true infection with Mycobacterium tuberculosis (Mtb) 41 
[3]. We present a patient who clearly illustrates the clinical significance of borderline QFT 42 
results in patients screened before immunosuppression. 43 
December 2017, a 33-year-old woman who was 33 weeks pregnant presented to Leiden 44 
University Medical Center with headache, spiking fever and night sweats since three weeks. 45 
She was born in Morocco and had moved to The Netherlands in 2003. She had ulcerative 46 
colitis for which she was treated with low dose prednisone, mesalazine and infliximab once 47 
per six weeks, the latter since June 2017. The temperature was 39.0 °C, but physical 48 
examination revealed no other abnormalities, in particular no neurological signs. Laboratory 49 
data showed a C-reactive protein of 56 mg/L (normal value: <10 mg/L) and a normal white-50 
cell count. A chest radiograph (CXR) showed hilar lymphadenopathy and a diffuse nodular 51 
pattern, suspect of miliary TB. Computed Tomography imaging of the brain showed no signs 52 
of cerebral TB and cerebrospinal fluid was without abnormalities. Standard quadruple TB 53 
therapy was immediately started. The QFT result was positive (TB1: 5.37 IU/mL, TB2: 5.55 54 
IU/mL). The clinical course is shown in Figure 1. Auramine staining and polymerase chain 55 
reaction for Mtb on gastric lavage fluid and sputum were positive. MGIT cultures of gastric 56 
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lavage fluid and sputum cultures became positive for Mtb after 15 days. Susceptibility testing 57 
later showed full susceptibility. 58 
 The pre anti-TNF screening was reviewed. Five months prior to admission she had been 59 
screened for LTBI in a local hospital, when she was not yet using any immunosuppressive 60 
therapy. The patient was BCG-vaccinated and had reported contact with a relative with active 61 
TB 20 years earlier. She had visited Morocco several times since 2003. Her tuberculin skin 62 
test result was 10 mm induration, which appeared to be overlooked by the attending 63 
physician, and QFT test result was negative (TB1: 0.11 IU/mL, TB2: 0.22 IU/mL). Because 64 
of the pregnancy, no CXR had been performed at that time. Thus no preventive therapy was 65 
started. The original colon biopsies were reviewed, but no granulomas were found. 66 
During TB treatment, mesalazine and prednisone were continued, but infliximab therapy 67 
was withheld. The patient had a favourable clinical response and 20 days later gave birth to a 68 
healthy daughter without signs of congenital TB and negative histology of the placenta. The 69 
new-born was given isoniazide preventive therapy which was discontinued after the 70 
tuberculin skin test was negative three months later. Variable-Number Tandem Repeat 71 
(VNTR) typing of the patient’s Mtb isolate was performed by the National Institute for Public 72 
Health and the Environment (RIVM), showing a unique VNTR number (9007047) which 73 
strongly argues in favour of exposure abroad. 74 
This patient who developed miliary TB during pregnancy and after starting infliximab, 75 
preceded by a negative QFT result in the borderline range, illustrates the clinical relevance of 76 
a borderline QFT in this setting. Infliximab is a monoclonal antibody directed against TNF-α. 77 
TNF-α plays a major role in recruitment and organisation of mononuclear cells into well-78 
structured granulomas. Anti-TNF therapy can result in disintegration of granulomas and 79 
reactivation TB [4]. However, this cannot be extrapolated directly to biologicals with a 80 
different mechanism of action and some, such as rituximab, are even considered safe in this 81 
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regard [5]. Yet, even in the screening era the risk has remained increased, probably reflecting 82 
suboptimal performance of diagnostic tests for LTBI in this setting [6]. In our patient the 83 
positive TST screening result was unfortunately overlooked. Of note, the effect of BCG 84 
vaccination, if given before one year of age, on the TST is negligible beyond ten years after 85 
vaccination [7]. Thus, the TST should have been qualified as true positive anyway, which 86 
was strengthened by the self-reported TB contact. According to the manufacturer’s cut-off, 87 
her QFT screening result of 0.22 IU/mL was indeed negative. This low value can be 88 
explained by the decreased sensitivity of QFT for detection of a remote Mtb infection [8]. 89 
However, recent studies showed that a result just below the cut-off includes patients with true 90 
Mtb infection [3, 9] and additional data support and extend this notion (manuscript in press). 91 
One retrospective study showed that individuals with a borderline QFT result (defined as 0.20 92 
to 0.34 IU/mL) developed active TB significantly more often compared to those with a 93 
negative result [10]. However, further research is needed to corroborate our observation, e.g. 94 
by retrospective analysis of quantitative QFT results in all patients who developed active TB 95 
despite screening. In our opinion, until more data are available, lowering the QFT cut-off 96 
should be limited to patients who will receive significant immunosuppression and should not 97 
be applied in normal or low risk settings. 98 
This case emphasizes the value of TST irrespective of BCG-vaccination and shows that a 99 
borderline QFT result in a patient screened before immunosuppression should be considered 100 
as a risk factor for reactivation TB. In this setting, a borderline QFT result with or without 101 
any other risk factor, be it origin, known exposure, past or present positive TST result and/or 102 
suggestive abnormalities on CXR, in our opinion justifies preventive therapy.  103 
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Legends 152 
Figure 1. Time line of the clinical course  153 
Abbreviations used: CSF: cerebrospinal fluid; HRZE: H= isoniazide, R=rifampicin, 154 
Z=pyrazinamide, E=ethambutol; LTBI: latent tuberculosis infection; MTB: Mycobacterium 155 
tuberculosis; PCR: polymerase chain reaction; QFT: QuantiFERON-TB Gold Plus; TB: 156 
tuberculosis; TST: tuberculin skin test; 157 
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To the Editor: 33 
Patients who are eligible for treatment with immunosuppressive drugs such as antagonists of 34 
tumour necrosis factor-α (TNF-α) must be screened for latent tuberculosis infection (LTBI), 35 
as stated in the recent European Standards for TB Care [1]. Although there are controversies 36 
regarding optimal screening [2], interferon gamma release assays (IGRA) such as 37 
QuantiFERON-TB Gold (QFT) are nowadays frequently used. The formal cut-off for a 38 
positive QFT is ≥ 0.35 IU/mL interferon-γ. However, a recent study published in European 39 
Respiratory Journal found that a significant proportion of results just below this cut-off, so 40 
called ‘borderline results’, represented true infection with Mycobacterium tuberculosis (Mtb) 41 
[3]. We present a patient who clearly illustrates the clinical significance of borderline QFT 42 
results in patients screened before immunosuppression. 43 
December 2017, a 33-year-old woman who was 33 weeks pregnant presented to Leiden 44 
University Medical Center with headache, spiking fever and night sweats since three weeks. 45 
She was born in Morocco and had moved to The Netherlands in 2003. She had ulcerative 46 
colitis for which she was treated with low dose prednisone, mesalazine and infliximab once 47 
per six weeks, the latter since June 2017. The temperature was 39.0 °C, but physical 48 
examination revealed no other abnormalities, in particular no neurological signs. Laboratory 49 
data showed a C-reactive protein of 56 mg/L (normal value: <10 mg/L) and a normal white-50 
cell count. A chest radiograph (CXR) showed hilar lymphadenopathy and a diffuse nodular 51 
pattern, suspect of miliary TB. Computed Tomography imaging of the brain showed no signs 52 
of cerebral TB and cerebrospinal fluid was without abnormalities. Standard quadruple TB 53 
therapy was immediately started. The QFT result was positive (TB1: 5.37 IU/mL, TB2: 5.55 54 
IU/mL). The clinical course is shown in Figure 1. Auramine staining and polymerase chain 55 
reaction for Mtb on gastric lavage fluid and sputum were positive. MGIT cultures of gastric 56 
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lavage fluid and sputum cultures became positive for Mtb after 15 days. Susceptibility testing 57 
later showed full susceptibility. 58 
 The pre anti-TNF screening was reviewed. Five months prior to admission she had been 59 
screened for LTBI in a local hospital, when she was not yet using any immunosuppressive 60 
therapy. The patient was BCG-vaccinated and had reported contact with a relative with active 61 
TB 20 years earlier. She had visited Morocco several times since 2003. Her tuberculin skin 62 
test result was 10 mm induration, which appeared to be overlooked by the attending 63 
physician, and QFT test result was negative (TB1: 0.11 IU/mL, TB2: 0.22 IU/mL). Because 64 
of the pregnancy, no CXR had been performed at that time. Thus no preventive therapy was 65 
started. The original colon biopsies were reviewed, but no granulomas were found. 66 
During TB treatment, mesalazine and prednisone were continued, but infliximab therapy 67 
was withheld. The patient had a favourable clinical response and 20 days later gave birth to a 68 
healthy daughter without signs of congenital TB and negative histology of the placenta. The 69 
new-born was given isoniazide preventive therapy which was discontinued after the 70 
tuberculin skin test was negative three months later. Variable-Number Tandem Repeat 71 
(VNTR) typing of the patient’s Mtb isolate was performed by the National Institute for Public 72 
Health and the Environment (RIVM), showing a unique VNTR number (9007047) which 73 
strongly argues in favour of exposure abroad. 74 
This patient who developed miliary TB during pregnancy and after starting infliximab, 75 
preceded by a negative QFT result in the borderline range, illustrates the clinical relevance of 76 
a borderline QFT in this setting. Infliximab is a monoclonal antibody directed against TNF-α. 77 
TNF-α plays a major role in recruitment and organisation of mononuclear cells into well-78 
structured granulomas. Anti-TNF therapy can result in disintegration of granulomas and 79 
reactivation TB [4]. However, this cannot be extrapolated directly to biologicals with a 80 
different mechanism of action and some, such as rituximab, are even considered safe in this 81 
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regard [5]. Yet, even in the screening era the risk has remained increased, probably reflecting 82 
suboptimal performance of diagnostic tests for LTBI in this setting [6]. In our patient the 83 
positive TST screening result was unfortunately overlooked. Of note, the effect of BCG 84 
vaccination, if given before one year of age, on the TST is negligible beyond ten years after 85 
vaccination [7]. Thus, the TST should have been qualified as true positive anyway, which 86 
was strengthened by the self-reported TB contact. According to the manufacturer’s cut-off, 87 
her QFT screening result of 0.22 IU/mL was indeed negative. This low value can be 88 
explained by the decreased sensitivity of QFT for detection of a remote Mtb infection [8]. 89 
However, recent studies showed that a result just below the cut-off includes patients with true 90 
Mtb infection [3, 9] and additional data support and extend this notion (manuscript in press). 91 
One retrospective study showed that individuals with a borderline QFT result (defined as 0.20 92 
to 0.34 IU/mL) developed active TB significantly more often compared to those with a 93 
negative result [10]. However, further research is needed to corroborate our observation, e.g. 94 
by retrospective analysis of quantitative QFT results in all patients who developed active TB 95 
despite screening. In our opinion, until more data are available, lowering the QFT cut-off 96 
should be limited to patients who will receive significant immunosuppression and should not 97 
be applied in normal or low risk settings. 98 
This case emphasizes the value of TST irrespective of BCG-vaccination and shows that a 99 
borderline QFT result in a patient screened before immunosuppression should be considered 100 
as a risk factor for reactivation TB. In this setting, a borderline QFT result with or without 101 
any other risk factor, be it origin, known exposure, past or present positive TST result and/or 102 
suggestive abnormalities on CXR, in our opinion justifies preventive therapy.  103 
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Legends 152 
Figure 1. Time line of the clinical course  153 
Abbreviations used: CSF: cerebrospinal fluid; HRZE: H= isoniazide, R=rifampicin, 154 
Z=pyrazinamide, E=ethambutol; LTBI: latent tuberculosis infection; MTB: Mycobacterium 155 
tuberculosis; PCR: polymerase chain reaction; QFT: QuantiFERON-TB Gold Plus; TB: 156 
tuberculosis; TST: tuberculin skin test; 157 
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